|
GB0622195D0
(en)
*
|
2006-11-08 |
2006-12-20 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
|
ES2524787T3
(es)
|
2007-11-15 |
2014-12-12 |
Msd Italia S.R.L. |
Derivados de piridazinona como inhibidores de PARP
|
|
DE102008019907A1
(de)
*
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
ES2590987T3
(es)
*
|
2009-04-29 |
2016-11-24 |
Glaxo Group Limited |
Derivados de 5,6,7,8-tetrahidro[1,2,4]triazolo[4,3-a]pirazina como moduladores de P2X7
|
|
GB0907515D0
(en)
*
|
2009-04-30 |
2009-06-10 |
Glaxo Group Ltd |
Compounds
|
|
EP2552920B1
(en)
*
|
2010-04-02 |
2017-03-15 |
Ogeda Sa |
Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
|
|
US10065960B2
(en)
|
2010-04-02 |
2018-09-04 |
Ogeda Sa |
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
|
|
JP2013526514A
(ja)
|
2010-05-10 |
2013-06-24 |
ラディカル・セラピューティックス・インコーポレイテッド |
リポ酸およびニトロキシド誘導体およびその使用
|
|
CN102372716A
(zh)
*
|
2010-08-09 |
2012-03-14 |
江苏恒瑞医药股份有限公司 |
酞嗪酮类衍生物、其制备方法及其在医药上的应用
|
|
EP2714703B1
(en)
|
2011-05-31 |
2021-03-10 |
Newgen Therapeutics, Inc. |
Tricyclic inhibitors of poly(adp-ribose)polymerase
|
|
WO2013050424A1
(en)
|
2011-10-03 |
2013-04-11 |
Euroscreen S.A. |
NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF
|
|
CN103570725B
(zh)
*
|
2012-08-01 |
2017-03-22 |
中国科学院上海药物研究所 |
哌嗪并三唑类化合物及其制备方法和用途
|
|
CN103833756B
(zh)
*
|
2012-11-26 |
2016-12-21 |
中国科学院上海药物研究所 |
一类哒嗪酮类化合物及其制备方法和用途
|
|
ES2469990B1
(es)
*
|
2012-12-19 |
2015-01-26 |
Universidade De Vigo |
Compuestos de estructura híbrida piridazinona ditiocarbamato con actividad antineoplásica
|
|
PL2938598T3
(pl)
*
|
2012-12-31 |
2017-05-31 |
Cadila Healthcare Limited |
Podstawione pochodne ftalazyn-1 (2H)-onu jako selektywne inhibitory polimerazy-1 poli(ADP-rybozy)
|
|
PT2975030T
(pt)
*
|
2013-03-13 |
2020-09-28 |
Chugai Pharmaceutical Co Ltd |
Derivado de di-hidropiridazina-3,5-diona
|
|
SG10201707409PA
(en)
|
2013-03-13 |
2017-10-30 |
Forma Therapeutics Inc |
Novel compounds and compositions for inhibition of fasn
|
|
US10183948B2
(en)
|
2013-03-29 |
2019-01-22 |
Ogeda Sa |
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
|
|
JP6275242B2
(ja)
|
2013-03-29 |
2018-02-07 |
オゲダ エス．エー． |
選択的ＮＫ−３受容体拮抗薬としての新規なＮ−アシル−（３位置換）−（８−メチル）−５，６−ジヒドロ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン、その医薬組成物、ＮＫ−３受容体媒介性障害で使用する方法
|
|
ES2711143T3
(es)
|
2013-03-29 |
2019-04-30 |
Ogeda Sa |
N-acil-(3-sustituido)-5,6,7,8-tetrahidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor de NK-3, composición farmacéutica, métodos para su uso en los trastornos mediados por el receptor de NK-3
|
|
PT2948455T
(pt)
|
2013-03-29 |
2017-11-15 |
Ogeda S A |
N-acil-(3-substituído)-(8-substituído)-5,6-diidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas de recetor nk-3 seletivos, composição farmacêutica, métodos para utilização em distúrbios mediados por recetor nk-3
|
|
KR101670126B1
(ko)
|
2013-09-13 |
2016-10-27 |
일동제약(주) |
신규 프탈라지논 유도체 및 그 제조방법
|
|
ES2544869B2
(es)
*
|
2014-03-04 |
2016-01-18 |
Universidade De Vigo |
Derivados de piridazin-3(2H)-ona inhibidores selectivos de la isoforma B de la monoaminooxidasa
|
|
EP3200792A4
(en)
|
2014-10-03 |
2018-05-09 |
The Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center |
Poly (adp-ribose) polymerase 1 inhibitors structurally unrelated to nad
|
|
US10472664B2
(en)
|
2014-10-03 |
2019-11-12 |
Institute For Cancer Research |
Screening assay for identification of poly(ADP-ribose) polymerase 1 inhibitors
|
|
JP6871169B2
(ja)
|
2015-03-02 |
2021-05-12 |
シナイ ヘルス システム |
相同組換え因子
|
|
JP6457696B2
(ja)
|
2015-07-23 |
2019-01-23 |
アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ |
癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用
|
|
CN106749261A
(zh)
|
2015-11-23 |
2017-05-31 |
中国科学院上海药物研究所 |
一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
|
|
WO2018162439A1
(en)
|
2017-03-08 |
2018-09-13 |
Onxeo |
New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
|
|
ES2747768T3
(es)
|
2017-03-20 |
2020-03-11 |
Forma Therapeutics Inc |
Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
|
|
CN109232575B
(zh)
*
|
2017-07-10 |
2022-01-25 |
中国科学院上海药物研究所 |
吡咯[1,2-b]哒嗪类化合物或其可药用盐及它们的用途
|
|
KR20200130856A
(ko)
|
2018-03-13 |
2020-11-20 |
옹쎄오 |
암 치료에서 획득한 내성에 대한 디베이트 분자
|
|
EP3788040B1
(en)
|
2018-04-30 |
2023-04-12 |
Ribon Therapeutics Inc. |
Pyridazinones as parp7 inhibitors
|
|
US12053458B2
(en)
|
2018-09-19 |
2024-08-06 |
Novo Nordisk Health Care Ag |
Treating sickle cell disease with a pyruvate kinase R activating compound
|
|
ES2989438T3
(es)
|
2018-09-19 |
2024-11-26 |
Novo Nordisk Healthcare Ag |
Activación de la piruvato cinasa R
|
|
TWI767148B
(zh)
|
2018-10-10 |
2022-06-11 |
美商弗瑪治療公司 |
抑制脂肪酸合成酶(fasn)
|
|
US10793554B2
(en)
|
2018-10-29 |
2020-10-06 |
Forma Therapeutics, Inc. |
Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
|
|
US12371421B2
(en)
|
2019-04-29 |
2025-07-29 |
Ribon Therapeutics, Inc. |
Solid forms of a PARP7 inhibitor
|
|
US20220378756A1
(en)
|
2019-09-19 |
2022-12-01 |
Forma Therapeutics, Inc. |
Activating pyruvate kinase r
|
|
KR20220109401A
(ko)
|
2019-10-30 |
2022-08-04 |
리본 테라퓨틱스 인코포레이티드 |
Parp7 억제제로서의 피리다진온
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
US11390608B2
(en)
|
2020-04-21 |
2022-07-19 |
Idience Co., Ltd. |
Crystalline forms of phthalazinone compound
|
|
US12060345B2
(en)
|
2020-04-21 |
2024-08-13 |
Idience Co., Ltd. |
Process for preparing a phthalazinone derivative and intermediates thereof
|
|
US12059419B2
(en)
|
2020-10-16 |
2024-08-13 |
Idience Co., Ltd. |
Pharmaceutical composition comprising phthalazinone derivatives
|
|
US12128035B2
(en)
|
2021-03-19 |
2024-10-29 |
Novo Nordisk Health Care Ag |
Activating pyruvate kinase R
|
|
CN117083274A
(zh)
*
|
2021-04-23 |
2023-11-17 |
四川海思科制药有限公司 |
一种并环杂环衍生物及其在医药上的应用
|
|
CN115477640A
(zh)
*
|
2021-05-31 |
2022-12-16 |
由理生物医药（上海）有限公司 |
作为parp7抑制剂的哒嗪酮类化合物
|
|
EP4378938A4
(en)
*
|
2021-07-29 |
2025-04-02 |
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. |
NEW PARP7 INHIBITOR AND USE THEREOF
|
|
US20240343727A1
(en)
*
|
2021-08-17 |
2024-10-17 |
InventisBio Co., Ltd. |
Pyridazinone or pyridinone compounds, preparation methods and uses thereof
|
|
US20230183216A1
(en)
*
|
2021-10-28 |
2023-06-15 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
CN115745971B
(zh)
*
|
2021-12-20 |
2024-07-30 |
北京华森英诺生物科技有限公司 |
Parp7抑制剂及其应用
|
|
AU2022451580B2
(en)
*
|
2022-04-01 |
2024-11-07 |
Novostar Pharmaceuticals, Ltd. |
Parp7 inhibitor and use thereof
|
|
CN119968364A
(zh)
*
|
2022-09-30 |
2025-05-09 |
阿兹卡拉疗法公司 |
哒嗪-3(2h)-酮和吡啶-2(1h)-酮parp抑制剂化合物
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
KR20260030809A
(ko)
|
2023-06-21 |
2026-03-06 |
테트라곤 바이오사이언시스 엘티디 |
Hr 능숙형 암을 치료하는 방법에 사용하기 위한 데옥시시티딘 유도체 및 parp 억제제를 포함하는 조합
|
|
IL326136A
(en)
|
2023-08-07 |
2026-03-01 |
Revolution Medicines Inc |
RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
|
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025217307A1
(en)
|
2024-04-09 |
2025-10-16 |
Revolution Medicines, Inc. |
Methods for predicting response to a ras(on) inhibitor and combination therapies
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|